Digital Defocus Vision Training (DDVT) System Development and Application
Launched by ZHONGSHAN OPHTHALMIC CENTER, SUN YAT-SEN UNIVERSITY · Jun 18, 2025
Trial Information
Current as of August 21, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • children aged 6 to 12 years
- • diagnosis of myopia with SER of -0.75 to -6.00 D
- • regular astigmatism, and astigmatism less than 2.50D
- • anisometropia less than 1.50 D
- • a logMAR best-corrected visual acuity (BCVA) of 0.00 or better
- • an understanding by participants and their legal guardians of the purpose of the study
- Exclusion Criteria:
- • other myopia control therapies in the last 6 months (including but not limited to atropine and orthokeratology)
- • strabismus, amblyopia, congenital lens dislocation, congenital cataract, glaucoma, uveitis, nystagmus, keratoconus, eye neoplasms and other ocular diseases
- • systemic diseases such as nephrotic syndrome or diabetes
- • structural changes in the eyeball, a history of ocular surgery or trauma
- • other systemic diseases affecting eye health
- • participants in other clinical trials at the same time.
About Zhongshan Ophthalmic Center, Sun Yat Sen University
The Zhongshan Ophthalmic Center, affiliated with Sun Yat-sen University, is a leading institution in ophthalmic research and clinical care in China. Renowned for its commitment to advancing the field of ophthalmology, the center specializes in innovative treatments and technologies for various eye conditions. With a strong emphasis on clinical trials, the center aims to enhance patient outcomes through rigorous scientific investigation and collaboration with global research networks. Its multidisciplinary team of experts is dedicated to fostering cutting-edge research that translates into effective therapeutic strategies for vision preservation and restoration.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, , China
Guangzhou, Guangdong, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported